Syndax Pharmaceuticals

Company

Last mentioned: Mar 6, 2026

Stories mentioning Syndax Pharmaceuticals 2

pharma Neutral

Kura Oncology and Profound Medical Q4 Results Reveal Divergent Growth Paths

Kura Oncology and Profound Medical reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial execution in precision oncology and medical technology. While both companies faced revenue headwinds, Kura's launch of KOMZIFTI and Profound's surprise earnings beat signal a maturing landscape for specialized therapies.

2 sources
market-trends Neutral

Kura and Profound Q4 Results: Pivotal 2026 for Precision Medicine

Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a critical transition period as they navigate commercial launches and reimbursement hurdles. While both firms faced revenue headwinds, Kura's $7 billion AML opportunity and Profound's significant EPS beat underscore a shifting landscape in oncology and incision-less surgery.

2 sources